U.S. markets open in 7 hours 51 minutes

Reata Pharmaceuticals, Inc. (RETA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
129.33+2.70 (+2.13%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close126.63
Open125.01
Bid0.00 x 1300
Ask0.00 x 800
Day's Range121.30 - 130.86
52 Week Range88.17 - 208.86
Volume301,005
Avg. Volume312,103
Market Cap4.671B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-11.19
Earnings DateMar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est243.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA
    Zacks

    Reata (RETA) Beats on Q4 Earnings, Submits Bardoxolone NDA

    Reata (RETA) reports encouraging fourth-quarter results wherein earnings and sales beat estimates. The company files NDA for lead candidate in Alport syndrome. Stock rises.

  • Reata Pharmaceuticals, Inc. (RETA) Q4 2020 Earnings Call Transcript
    Motley Fool

    Reata Pharmaceuticals, Inc. (RETA) Q4 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by and welcome to the Reata Pharmaceuticals Fourth Quarter Financial and Full Year 2020 Financial Results and Update on Development Programs Conference Call. An audio recording of today's webcast will be available shortly after the call today on Reata's website at reatapharma.com in the Investors section.

  • Benzinga

    Reata Pharma Shares Are Trading Higher After Filing US Application In Alport Syndrome-Related Kidney Disease

    Reata Pharmaceuticals Inc (NASDAQ: RETA) has submitted a marketing application to the FDA for bardoxolone methyl (bardoxolone) to treat chronic kidney disease caused by Alport syndrome. Alport syndrome is a rare, genetic form of kidney disease caused by mutations in the genes encoding type IV collagen, a major structural component of the kidney's glomerular basement membrane. The kidneys of patients with Alport syndrome progressively lose the capacity to filter waste products out of the blood, leading to end-stage kidney disease. In November last year, the company announced positive Phase 3 CARDINAL study results. Data demonstrated that patients treated with bardoxolone experienced a statistically significant improvement in kidney function measured by eGFR at Week 100 and Week 104, compared to patients treated with placebo. Price Action: RETA shares are up 5.4% at $128.81 in market trading hours on the last check Monday. See more from BenzingaClick here for options trades from BenzingaFluidigm Gets EUA Nod For Home Sample Collection Kit For Advanta COVID-19 AssayAvadel's US Application In Sleep Disorder Accepted For Review© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.